$ACOG News
Last published 2h ago
- 2h agoACOGAlpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational UpdateBusiness WireVANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update. “The third quart ...
- 2d agoACOGAlpha Cognition Strengthens Its Board of Directors with Appointment of Caren DeardorfBusiness WireVANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Caren Deardorf to its Board of Directors, effective Nov 9, 2026. Ms. Deardorf brings decades of leadership experie ...
- 5d agoACOGAlpha Cognition to Participate in Upcoming Investor EventsBusiness WireVANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, and Lauren D’Angelo, Chief Operating Officer, will participate in the up ...
- 4w agoACOGAlpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®Business WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today
- 1mo agoACOGAlpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall CongressBusiness WirePresentations will highlight data on cognition, function, neuropsychiatric symptoms, sleep, gastrointestinal tolerability, treatment patterns and psychotropic medication utilization in Alzheimer’s disease Alpha
- 1mo agoACOGAlpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today
- 1mo agoACOGAlpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term CareBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using
- 2mo agoACOGAlpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today
- 2mo agoACOGAlpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today
- 3mo agoACOGAlpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational UpdateBusiness WireZUNVEYL® net product revenue increased approximately 71% quarter-over-quarter to $6.0 million in the second quarter of 2026. Bottles dispensed increased approximately 37% quarter-over-quarter to 8,294, with monthly
- 3mo agoACOGAlpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business UpdateBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and
- 3mo agoACOGAlpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s DiseaseBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced
- 4mo agoACOGAlpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision SummitBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced
- 4mo agoACOGMISTCBAYONCTAlpha Cognition Announces Election of Dr. Robert Wills as Chairman of the BoardBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced
- 4mo agoACOGAlpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's DiseaseBusiness WireAlpha Cognition, Inc. (ACOG: NASDAQ) ("Alpha Cognition" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the
- 5mo agoACOGAlpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's DiseaseBusiness WireIn a retrospective observational study based on provider assessments and chart review: Providers reported cognitive improvement in 92% of patients following initiation of ZUNVEYL Providers reported improvement in
- 6mo agoACOGAlpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational UpdateBusiness WireZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase Cumulative net product revenue totaled $10.3 million through first four full quarters of launch Q1 2026 bottles
- 6mo agoACOGAlpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026Business WireManagement to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today
- 6mo agoACOGAlpha Cognition Inc. to Participate in Three Upcoming Investor ConferencesBusiness WireAlpha Cognition, Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael
- 6mo agoACOGKALVSUPNAlpha Cognition Strengthens Its Board of Directors with Appointment of Bethany SensenigBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment
- 7mo agoACOGAlpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on April 14,
- 7mo agoACOGAlpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain InjuryBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the United
- 7mo agoACOGAlpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational UpdateBusiness WireAlpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million Fourth quarter bottles dispensed increased 62%
- 8mo agoACOGAlpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026Business WireManagement to host conference call on Thursday, March 26, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today
- 8mo agoACOGAlpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International ConferencesBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new
- 8mo agoACOGAlpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness StudyBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition," "ACI," or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced
- 8mo agoACOGAlpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing RegimensBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition," "ACI," or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the
- 11mo agoACOGAlpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan PartnersBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Alpha Cognition
- 12mo agoACOGAlpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational UpdateBusiness WireKey Highlights ZUNVEYL Launch Momentum: Completed the second quarter of commercialization, generating approximately $2.8 million in total revenue for the quarter. Significant Growth: 102% quarterly increase in
- 1y agoACOGAlpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025Business WireManagement to host conference call on Thursday, November 13, 2025 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today
- 1y agoACOGAlpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute MeetingsBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new
- 1y agoACOGAlpha Cognition to Present Clinical Data at ASCP Annual MeetingBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG), a commercial-stage biopharmaceutical company developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors
- 1y agoACOGAlpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common SharesBusiness WireOffering was led by an initial investment from a premier healthcare-dedicated investor alongside multiple large existing shareholders Company's total cash position expected to be approximately $70 million following
- 1y agoACOGAlpha Cognition Inc. Announces Proposed Public Offering of Common SharesBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) (the "Company"), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that it is proposing to
- 1y agoACOGAlpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor ConferencesBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that Chief Executive Officer Michael
- 1y agoACOGAlpha Cognition Inc. (ACOG) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoACOGAlpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational UpdateBusiness WireKey Highlights ZUNVEYL Launch Momentum: Completed the first quarter of ZUNVEYL commercialization, achieving approximately $2 million in net product revenues year-to-date. Advancing ALPHA-1062: Completed
- 1y agoACOGAlpha Cognition to Report Second Quarter 2025 Financial Results and Operating OverviewBusiness WireConference Call Scheduled for August 14, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will
- 1y agoACOGAlpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer's DiseaseBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" [ACI], or the "Company"), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced China Medical System
- 1y agoACOGAlpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International ConferenceBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new
- 1y agoACOGAlpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain InjuryBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" [ACI], or the "Company"), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced preclinical data
- 1y agoACOGAlpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating OverviewBusiness WireLaunched ZUNVEYL (benzgalantamine) to US market on March 17, 2025 Secured business development licensing revenues of $2.6M for partnership with CMS Pharma Cash and cash equivalents of $45.5 million as of March 31,
- 1y agoACOGAlpha Cognition to Report First Quarter 2025 Financial Results and Operating OverviewBusiness WireConference Call Scheduled for May 15, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial
- 1y agoACOGCBAYMISTONCTAlpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John HavensBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment
- 1y agoACOGAlpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating OverviewBusiness WireRaised $52.8 million in gross proceeds in Q4 2024 to support the upcoming ZUNVEYL commercial launch and Nasdaq uplisting (symbol: ACOG). Completed commercial manufacturing to support the ZUNVEYL
- 1y agoACOGAlpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating OverviewBusiness WireConference Call Scheduled for March 31, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will
- 1y agoACOGAlpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's DiseaseBusiness WireZUNVEYL is the first oral FDA-approved treatment for Alzheimer's disease in the past decade 32 person sales team hired to cover the $2 billion Long-Term-Care market All launch activities delivered on-time and
- 1y agoACOGAlpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's diseaseBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United
- 1y agoACOGAlpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYLBusiness WireAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic
- 1y agoACOGAlpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in ChinaBusiness WireAlpha Cognition, Inc. (NASDAQ:ACOG) ("ACI" or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and China Medical System Holdings Limited (CMS)